Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Manjit McNeill"'
Autor:
Timothy M, Miller, Merit E, Cudkowicz, Angela, Genge, Pamela J, Shaw, Gen, Sobue, Robert C, Bucelli, Adriano, Chiò, Philip, Van Damme, Albert C, Ludolph, Jonathan D, Glass, Jinsy A, Andrews, Suma, Babu, Michael, Benatar, Christopher J, McDermott, Thos, Cochrane, Sowmya, Chary, Sheena, Chew, Han, Zhu, Fan, Wu, Ivan, Nestorov, Danielle, Graham, Peng, Sun, Manjit, McNeill, Laura, Fanning, Toby A, Ferguson, Stephanie, Fradette, Cathy, Zhong
Publikováno v:
The New England journal of medicine. 387(12)
The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis (ALS) associated with mutations inIn this phase 3 tri
Autor:
Robert C. Bucelli, Manjit McNeill, Shafeeq Ladha, Angela Genge, Stephanie Fradette, Ivan Nestorov, John Ravits, Philip Van Damme, Roger Lane, Christopher J McDermott, Jonathan Glass, Merit Cudkowicz, Laura Fanning, C. Frank Bennett, Heiko Runz, Ih Chang, Hani Houshyar, Toby A. Ferguson, Alfred Sandrock, Alan Pestronk, Danielle Graham, Timothy M. Miller, Randall G. Trudell, Nazem Atassi, Peter M. Andersen, François Salachas, Nicholas J. Maragakis, Albert L. Ludolph, Pamela J. Shaw, Lorne Zinman, Alexander McCampbell
Publikováno v:
New England Journal of Medicine. 383:109-119
Background Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis. Intrathecal administratio...
Autor:
Pamela Shaw, Timothy Miller, Merit Cudkowicz, Angela Genge, Gen Sobue, Ivan Nestorov, Dan- ielle Graham, Laura Fanning, Stephanie Fradette, Manjit McNeill
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 93:e2.208
VALOR was a Phase 3, placebo-controlled trial to evaluate the clinical efficacy and safety of tofersen in adults with ALS and a confirmed SOD1 mutation (SOD1-ALS). Participants were randomised 2:1 to tofersen 100 mg (3 doses ~2 weeks apart, then 5 do
Autor:
Ih Chang, Rachel Farrell, Jacob Elkins, Veronica Englishby, Jeremy Hobart, Manjit McNeill, Gabriel Paiva da Silva Lima, Raymond Hupperts, Peter Feys, Tjalf Ziemssen, Andrew D. Goodman, Andrew R. Blight, Michael Linnebank
Publikováno v:
CNS Drugs
Cns Drugs, 33(1), 61-79. Adis International Ltd
Cns Drugs, 33(1), 61-79. Adis International Ltd
Background Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment i
Autor:
Timothy, Miller, Merit, Cudkowicz, Pamela J, Shaw, Peter M, Andersen, Nazem, Atassi, Robert C, Bucelli, Angela, Genge, Jonathan, Glass, Shafeeq, Ladha, Albert L, Ludolph, Nicholas J, Maragakis, Christopher J, McDermott, Alan, Pestronk, John, Ravits, François, Salachas, Randall, Trudell, Philip, Van Damme, Lorne, Zinman, C Frank, Bennett, Roger, Lane, Alfred, Sandrock, Heiko, Runz, Danielle, Graham, Hani, Houshyar, Alexander, McCampbell, Ivan, Nestorov, Ih, Chang, Manjit, McNeill, Laura, Fanning, Stephanie, Fradette, Toby A, Ferguson
Publikováno v:
The New England journal of medicine. 383(2)
Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral s
Autor:
Manjit McNeill, Tjalf Ziemssen, Peter Feys, Jeremy Hobart, Jan Lycke, Carlos Acosta, Raymond Hupperts, Claudio Gasperini
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 90:e48.4-e49
IntroductionThe MOBILE and ENHANCE studies evaluated prolonged-release fampridine (PR-FAM) vs placebo (MOBILE, n=68 vs 64; ENHANCE, n=315 vs 318) in people with multiple sclerosis (PwMS) over 24 weeks. PR-FAM-associated improvements in walking and ph
Autor:
Gavin, Giovannoni, Ralf, Gold, Krzysztof, Selmaj, Eva, Havrdova, Xavier, Montalban, Ernst-Wilhelm, Radue, Dusan, Stefoski, Manjit, McNeill, Lakshmi, Amaravadi, Marianne, Sweetser, Jacob, Elkins, Gilmore, O'Neill, E, Silber
Publikováno v:
The Lancet Neurology. 13:472-481
Summary Background In the SELECT trial, disease activity was reduced in patients with multiple sclerosis who received daclizumab high-yield process (HYP) for 52 weeks. The primary aim of the SELECTION extension study was to assess the safety and immu
Autor:
Raymond Hupperts, Claudio Gasperini, John Zhong, Lahar Mehta, Jan Lycke, Manjit McNeill, Christine Short
Publikováno v:
Journal of the Neurological Sciences, 370, 123-131. Elsevier Science
Prolonged-release (PR) fampridine is approved to treat walking impairment in persons with multiple sclerosis (MS); however, treatment benefits may extend beyond walking. MOBILE was a phase 2, 24-week, double-blind, placebo-controlled exploratory stud
Autor:
Lahar Mehta, Manjit McNeill, Kathleen W. Wyrwich, Priscilla Auguste, John Zhong, Jacob Elkins, Jiat-Ling Poon, Jeremy Hobart
Publikováno v:
Multiple sclerosis journal-experimental, translational and clinical
Background The 12-question Multiple Sclerosis Walking Scale (MSWS-12v1) is a widely-used patient-reported outcome (PRO) measure of walking ability in multiple sclerosis (MS). Objective To estimate the magnitude of an important change in MSWS-12v1 sco
Autor:
Manjit McNeill, Jeremy Hobart, Michael Linnebank, Gabriel Paiva da Silva Lima, C. Acosta, Raymond Hupperts
Publikováno v:
Journal of the Neurological Sciences. 381:452